Skyepharma partners with Mundipharma to develop SKP-2076
UK drug delivery company Skyepharma (LSE: SKP) on Wednesday said it has partnered with Mundipharma Laboratories to develop product in a pressurized Metered Dose Inhaler (pMDI).
Under the terms of the agreement, Skyepharma is responsible for certain feasibility work which is planned to be completed in the second-quarter 2016.
Peter Grant, chief executive of Skyepharma, said:“This new partnership further expands our excellent relationship with Mundipharma based on our successful collaboration on flutiform, which is growing well in multiple markets. The triple combination is a natural extension of the flutiform franchise and we believe it has the potential to provide an important additional treatment option for doctors and patients. SKP-2076 is a great example of innovation at Skyepharma, leveraging our expertise and strong relationships with partners to generate benefits for patients and value for shareholders.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze